Injectable Diltiazem Recalled Over Sterility Assurance Concerns from FDA Inspection
Central Admixture Pharmacy Services is recalling 3,040 bags of prescription diltiazem injection after FDA inspection raised concerns about product sterility. The medication was distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of a sterile injectable product where inspection confirmed concerns about sterility assurance. No illnesses or injuries have been reported, but loss of sterility assurance in an injectable medication presents significant risk of contamination and serious infection.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 3,040 bags of diltiazem added to 0.9% sodium chloride (125 mg/125 mL, 125 mL per bag). This is a prescription injectable medication.
The recall was initiated after a U.S. Food and Drug Administration (FDA) inspection raised concerns about whether the product meets sterility standards required for injectable medications. Injectable drugs must be sterile and free of harmful microorganisms to ensure patient safety. No illnesses or injuries have been reported in connection with this recall.
The affected product was distributed nationwide. The recalled lot numbers with expiration dates are: 37-896374, 37-896375 (05/31/2023); 37-896876, 37-896878 (06/02/2023); 37-897077, 37-897078 (06/05/2023); 37-900074, 37-900075, 37-900076, 37-900111, 37-900112, 37-900115 (06/15/2023); and 37-900328 (06/16/2023).
Healthcare providers and patients who have the recalled product should contact their pharmacy or healthcare provider immediately for instructions. Do not use any of the recalled lot numbers.
The recalled product
- Product
- dilTIAZem added to 0.9% sodium chloride, 125 mg/125 mL* (1 mg/mL), 125 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-6055-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable medication
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (18)
- Lot # 37-896374
- 37-896375
- Exp 05/31/2023
- 37-896876
- 37-896878
- Exp 06/02/2023
- 37-897077
- 37-897078
- Exp 06/05/2023
- 37-900074
- 37-900075
- 37-900076
- 37-900111
- 37-900112
- 37-900115
- Exp 06/15/2023
- 37-900328
- Exp 06/16/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27